Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) traded up 0.5% during mid-day trading on Tuesday . The company traded as high as $43.20 and last traded at $42.27, with a volume of 241,746 shares. The stock had previously closed at $42.06.

A number of analysts recently issued reports on the stock. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Five Prime Therapeutics in a report on Monday, April 18th. Zacks Investment Research downgraded shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, April 20th. BMO Capital Markets assumed coverage on shares of Five Prime Therapeutics in a report on Tuesday, April 12th. They set a “market perform” rating and a $50.00 price target on the stock. Credit Suisse Group AG reissued a “buy” rating on shares of Five Prime Therapeutics in a report on Wednesday, June 8th. Finally, Jefferies Group reissued a “buy” rating on shares of Five Prime Therapeutics in a report on Sunday, May 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $45.80.

The stock’s 50-day moving average is $42.32 and its 200-day moving average is $39.32. The company has a market cap of $1.15 billion and a price-to-earnings ratio of 4.83.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its earnings results on Thursday, May 5th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.22. The business earned $6.50 million during the quarter, compared to analyst estimates of $5.26 million. The business’s revenue was up 51.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.44) earnings per share. On average, analysts predict that Five Prime Therapeutics Inc. will post ($2.64) EPS for the current year.

In other Five Prime Therapeutics news, CFO Marc Belsky sold 34,102 shares of the business’s stock in a transaction on Friday, April 22nd. The shares were sold at an average price of $50.00, for a total value of $1,705,100.00. Following the transaction, the chief financial officer now directly owns 88,410 shares of the company’s stock, valued at approximately $4,420,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Franklin M. Berger acquired 6,090 shares of the company’s stock in a transaction on Tuesday, April 19th. The stock was purchased at an average cost of $47.06 per share, for a total transaction of $286,595.40. Following the completion of the purchase, the director now directly owns 77,890 shares in the company, valued at approximately $3,665,503.40. The disclosure for this purchase can be found here.

A number of institutional investors have recently made changes to their positions in FPRX. Marshall Wace LLP boosted its position in shares of Five Prime Therapeutics by 43.0% in the fourth quarter. Marshall Wace LLP now owns 237,141 shares of the company’s stock valued at $9,841,000 after buying an additional 71,262 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of Five Prime Therapeutics by 10.9% in the fourth quarter. GSA Capital Partners LLP now owns 72,200 shares of the company’s stock valued at $2,996,000 after buying an additional 7,086 shares in the last quarter. EAM Investors LLC purchased a new position in shares of Five Prime Therapeutics during the fourth quarter valued at about $1,549,000. ProShare Advisors LLC boosted its position in shares of Five Prime Therapeutics by 16.9% in the fourth quarter. ProShare Advisors LLC now owns 25,418 shares of the company’s stock valued at $1,055,000 after buying an additional 3,682 shares in the last quarter. Finally, Oxford Asset Management purchased a new position in shares of Five Prime Therapeutics during the fourth quarter valued at about $1,241,000.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.